CHIN-HSIAO TSENGChen C.-J.Landolph Jr. J.R.2020-06-012020-06-0120121687-5214https://www.scopus.com/inward/record.uri?eid=2-s2.0-84867824838&doi=10.1155%2f2012%2f101802&partnerID=40&md5=38907250cb67a8e2b9327acec418728chttps://scholars.lib.ntu.edu.tw/handle/123456789/496123[SDGs]SDG3antineoplastic agent; CA 19-9 antigen; exendin 4; liraglutide; metformin; prostate specific antigen; testosterone; androgen deprivation therapy; breast cancer; cancer hormone therapy; cancer risk; Caucasian; colon cancer; diabetes mellitus; dyslipidemia; editorial; embryonic stem cell; glycemic control; human; insulin resistance; liver cancer; lung cancer; neoplasm; nonhuman; pancreas cancer; priority journal; prostate cancer; thyroid cancer; animal; comorbidity; diabetes mellitus; hyperglycemia; metabolism; neoplasm; pathophysiology; risk; Animals; Comorbidity; Diabetes Mellitus; Humans; Hyperglycemia; Neoplasms; Riskeditorial10.1155/2012/101802230820752-s2.0-84867824838